CMS is approving this time-limited state plan amendment to respond to the COVID-19 national emergency.  The purpose of this amendment is to waive pharmacy signatures during a portion of the PHE (3/20/20 - 12/15/21).

CMS is approving this time-limited state plan amendment to respond to the COVID-19 national emergency.  The purpose of this amendment is to rescind the election of a separate increased reimbursement rate for Nursing Homes Facilities during the COVID-19 state of emergency.

This amendment is regarding clinical trials and is in compliance with SMD # 21-005, as it relates to the Consolidated Appropriations Act, 2021 (Public Law 116-260).

CMS is approving this time-limited state plan amendment to respond to the COVID-19 national emergency.  The purpose of this amendment is to waive signature requirements related to dispensing of drugs during the COVID-19 public health emergency.

The state proposes to include an assurance that the state covers routine patient costs for items and services furnished in connection with participation by Medicaid beneficiaries in qualifying clinical trials.

This State Plan Amendment provides required assurances that the state is appropriately covering and paying for routine patient costs of items and services for beneficiaries enrolled in qualifying clinical trials.

This amendment was to comply with the Consolidated Appropriations Act for 2021, which amended the Medicaid statute to add as a mandatory benefit, in both state plan and benchmark and benchmark equivalent coverage, for “routine patient costs for items and services furnished in connection with a qualifying clinical trial.